Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04619706 · ClinicalTrials.gov registry record · Phase 2
Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19
A Phase 2 study, sponsored by Quantum Biopharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT04619706 is a Phase 2 study that was terminated before completion, run by Quantum Biopharma. The registered enrollment target is 53 participants.
The verdict
NCT04619706, a Phase 2 study, was terminated before completion, sponsored by Quantum Biopharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This study will measure the effect of FSD201 (ultramicronized PEA) + SoC vs placebo + SoC on Day 28, on disease progression in the confirmed coronavirus disease 2019 (COVID-19) patient population.
Interventions
- DRUG Placebo
- DRUG FSD201
- OTHER Standard of Care for Covid-19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2021-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04619706
The ClinicalTrials.gov registry entry for NCT04619706 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quantum Biopharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04619706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04619706 about?
NCT04619706 is a clinical study titled "Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19". This study will measure the effect of FSD201 (ultramicronized PEA) + SoC vs placebo + SoC on Day 28, on disease progression in the confirmed coronavirus disease 2019 (COVID-19) patient population.
What is the current status of trial NCT04619706?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2020-12-14. Estimated completion is 2021-08-24.
What interventions are being tested in trial NCT04619706?
The interventions under investigation include: Placebo (DRUG), FSD201 (DRUG), Standard of Care for Covid-19 (OTHER).
Who is sponsoring clinical trial NCT04619706?
This trial is sponsored by Quantum Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.